nirsevimab

Overview

Nirsevimab is a long-acting monoclonal antibody used for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants. It is designed as an immunoprophylactic therapy rather than a traditional vaccine: instead of stimulating the host to generate its own antibody response, it provides immediate passive protection through direct administration of an RSV-neutralizing antibody. Its clinical role is especially important in early infancy, when the risk of severe RSV disease is highest and when active immune responses may be less predictable.

Biologically, nirsevimab targets the RSV fusion (F) protein in its prefusion conformation, thereby blocking viral entry into host cells. Because it has been engineered for extended half-life, a single dose can provide protection across much of the RSV season. In recent public health practice, nirsevimab has been discussed alongside maternal RSVpreF vaccination as part of broader infant RSV prevention strategies.

Recent Publications Summary

Recent publications on nirsevimab have focused on its real-world effectiveness, implementation, safety, economics, and emerging resistance in infant RSV prevention. A population-based cost-benefit analysis in the Community of Madrid, using administrative, clinical, vaccination, and surveillance data from 37,689 newborns and modeling uncertainty with Monte Carlo simulation, found lower incidence density of healthcare events among immunized children and reported an internal rate of return of 62% under the evaluated dose-price scenarios 42399582Jul. In Japan, a mixed-strategy economic and public health analysis examined national RSV prevention approaches combining maternal immunization and nirsevimab, reflecting the country’s shift from high-risk-targeted prophylaxis toward broader infant RSV prevention 42334170Jun. Similar comparative modeling was also undertaken in Sweden and temperate Western Australia to assess nirsevimab alone, maternal RSVpreF vaccination alone, and hybrid programs, underscoring ongoing efforts to define the most efficient RSV immunization strategy for infants 42258348Jun42176437May.

Several studies addressed uptake and programmatic implementation of nirsevimab in routine practice. In Ireland’s national Pathfinder pilot universal newborn immunisation programme, investigators assessed nirsevimab uptake and socio-demographic and perinatal predictors of receipt 42331576Jun. In Australia, a retrospective cohort study of 5,116 infants born at Sunshine Coast University Hospital found that 71.7% received valid RSV immunisation, with 45.2% protected through nirsevimab only; coverage remained stable overall while the composition shifted after introduction of antenatal Abrysvo, with neonatal nirsevimab accounting for all RSV coverage before Abrysvo became available 42184438May. Survey-based studies in Italy and Greece further examined acceptance and professional readiness for RSV immunization, reporting that many postpartum women viewed the monoclonal antibody as useful for newborn protection and that pediatricians had generally high knowledge but still showed gaps related to newly introduced immunoprophylaxis tools 42268596Jun42043589Apr.

Clinical effectiveness and safety were also prominent themes. A population-based retrospective cohort study compared nirsevimab immunisation after birth with maternal RSVpreF vaccination for preventing RSV-related hospitalisations in infants before 6 months of age 42107385May. An interim randomized trial evaluated maternal RSV vaccination, infant nirsevimab, or both, reflecting interest in sequential or combined use of the two preventive approaches 42070784May. Post-licensure safety surveillance from Canada’s CANVAS network found that local injection-site reactions were the most common short-term event after nirsevimab, were more frequent when co-administered with routine vaccines, and that more significant reactions were uncommon 42048598Apr.

Finally, one multicentre observational study in France investigated breakthrough RSV-B infections and the real-world emergence of nirsevimab resistance during the 2024–25 season, using genotypic and phenotypic methods to characterize escape variants 42229496Jun. Together, these publications indicate that nirsevimab is being studied not only as an effective RSV preventive therapy for infants, but also as a component of broader immunization strategies, with ongoing attention to uptake, safety, cost-effectiveness, and resistance surveillance 42399582Jul42334170Jun42048598Apr42229496Jun.

What Changes, What Holds

1. Nirsevimab is moving from a single-product prophylaxis to part of costed infant RSV prevention programs
NEW DIRECTION Economic and policy analyses suggest the antibody’s role is no longer being judged only by biological efficacy, but by how it fits into population-level prevention packages, budget impact, and return on investment. That extends the Overview’s prevention framing into implementation economics, while leaving its mechanism and infant use intact. The new work supports broader planning around nirsevimab, but does not by itself settle which national strategy is best 42399582Jul42334170Jun.

2. Real-world uptake now looks like the main constraint on benefit, not the antibody’s availability alone
METHOD These implementation studies do not change what nirsevimab is; they show how coverage, timing, and provider or parent acceptance determine whether the established preventive effect is actually delivered in routine care. The practical message is that effectiveness depends on program design and uptake, especially as antenatal vaccination enters the same space. That sharpens the Overview’s public-health context without contradicting it 42331576Jun42184438May.

3. Nirsevimab and maternal RSV vaccination should be viewed as competing and potentially complementary options, but the best sequencing remains unsettled
NEW DIRECTION Comparative effectiveness, interim trial data, and safety surveillance move the discussion beyond the Overview’s simple pairing of nirsevimab with maternal RSVpreF vaccination. The new work asks whether infant antibody, maternal immunization, or both together should be used, and it suggests that coadministration can increase local reactions while still remaining generally well tolerated. That adds a decision problem the baseline did not resolve 42107385May42070784May42048598Apr.

4. Escape variants mean nirsevimab protection may require ongoing resistance surveillance
NEW DIRECTION Breakthrough RSV-B infections with genotypic and phenotypic resistance findings add a new limitation to the Overview’s account of durable seasonal protection. The antibody still targets the prefusion F protein as described, but real-world viral evolution can erode that benefit, so effectiveness can no longer be assumed to be uniformly stable across seasons. This does not overturn the mechanism; it shows that surveillance for resistance is now part of responsible use 42229496Jun.

Overview update candidates: cost-effectiveness and program design as part of infant RSV prevention; comparative use of nirsevimab with maternal RSV vaccination; resistance surveillance as a routine consideration.